Chief Scientific Officer & Chief Operating Officer, Cennerv Pharma
Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Medicinal Chemistry.Register Now
The Medicinal Chemistry Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Head of Chemistry, Shanghai Discovery Center, Johnson & Johnson
Dr. Zhao-Kui (ZK) Wan, Ph.D.; FRSC
Dr. Wan is currently the Head of Chemistry at Johnson & Johnson’s Shanghai Discovery Center, prior to which he worked at Pfizer for a dozen years. Dr. Wan received his Ph.D. degree from Boston University, and then conducted a postdoctoral research at Harvard University where he discovered the sulfonamidebased asymmetric Nozaki-Hiyama-Kishi reaction. Dr. Wan contributed to the development of Eribulin that is now approved for the treatment of breast cancer and sarcoma under the name of Halaven™.
Dr. Wan’s has research experiences in multiple therapeutic areas, including inflammation, immunology, oncology, virology as well as cardiovascular and metabolic diseases. He has made significant contributions to the development a number of clinical and preclinical candidates.
Dr. Wan has more than 70 scientific publications in peer-reviewed journals, patents and meeting abstracts. He is an ad hoc reviewer for a number of prestigious scientific journals and serves on the Editorial board for North American Journal of Medicine & Health.
Dr. Wan is a cofounder, a member of Board of Directors of Chinese BioMedical Association (CABA) and served as the President (20092010). He was an Executive Committee member for Sino-American Professionals Association-New England (SA-PANE).
Dr. Wan has won a number of awards, including Young Industrial Investigator in 2008 by the American Chemistry Society, and Fellow of the Royal Society of Chemistry in 2015 by the Royal Society of Chemistry.
CSO & Executive Director, Orchid Pharma
Dr.Balasubramanian Gopalan, a Ph.D. in the year 1973 from University of Madras in Synthetic Organic Chemistry and worked as Post Doctoral fellow in Harvard University with Nobel laurite E.J.Corey and then switched over to the industry and joined Syntex Research Inc., California and Bristol-Myers Squibb in New Jersey, USA. He returned to India in the year 1982 and headed drug discovery division of Boots Pharmaceuticals Ltd., Sun Pharma Advanced Research Centre, Glaxo Ltd., Glenmark Research Centre, Matrix Laboratories and finally join as Executive Director and Chief of Orchid Chemicals & Pharmaceuticals in the year 2008. His achievements include discoveries of many new drugs that are in Phase-2 and Phase-3 clinical trial. Many of these discoveries such as Oglemilast (a novel PDE IV inhibitor) was out-licensed to Forest Laboratories, USA for US$190 million over a period of five years & also to Teijin of Japan for US$53 million.
Other of his drug melogliptin a new DPP4 for type 2 diabetes was out-licensed to Merck Germany for US$231 million. He has been a visiting fellow and elected fellow of many academics and universities to his credit he has 50 international patents.
He shares his expertise by training local talents in drug discovery research from Orchid chemical & Pharmaceuticals Ltd., OMR, Chennai.
A global informatics solution and service provider that was founded in 2005 as a spin-out from a multinational pharmaceutical company
Medicinal Chemistry Strategy Meeting APAC 2016,
22 Orange Grove Rd, Singapore 258350